An observational study in Acute-On-Chronic Liver Failure, sponsored by Hospital El Cruce. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-12-10.
Sponsored by Hospital El Cruce · Observational
Patients with Acute on Chronic Liver Failure (ACLF) have high short-term mortality. The use of a severity score could define the patient's prognosis and would help determine in whom the treatment is effective or futile.
Acute on Chronic Liver Failure (ACLF) is a syndrome characterized by the presence of an acute decompensation of cirrhosis, associated with failure of at least one other organ or extra hepatic system. It is characterized by high mortality in the short term and its prevalence varies between countries and regions.
It is an extraordinarily dynamic entity in which more than 50% of patients with less severe forms improve, while in those with 3 or more organ failures, the transplant rate is low and mortality is 90%. It is important to highlight that those patients with ACLF who manage to be transplanted have the same survival as cirrhotic patients without ACLF. There is no specific treatment, only life support and early determination of the precipitating factor and its eventual resolution.
Having tools that define the short-term prognosis of these patients, especially the variation of the score (CLIF-C ACLF) during the first week, would have an important clinical relevance, because it can help define the patients who benefit from the supportive treatment and in whom the therapeutic effort is futile.
The biomarker Neutrophil Gelatinase-Associated Lipocalin (NGAL) is increased in plasma and urine in patients with ACLF and could help improve the prognostic ability of the CLIF-C ACLF score.
445 studies on the registry are indexed under Liver Failure; 69 are open to participants now.
This study's planned enrollment of 30 is below the median of 129 across 146 observational studies indexed under Liver Failure.
Browse Liver Failure studies →Hospital El Cruce is the lead sponsor of 15 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with liver cirrhosis with ACLF over 18 years.
Exclusion Criteria:
Evaluate the degree of severity of the ACLF with the CLIF-C ACLF score at the time of diagnosis and its variation on day 3 and 7
The severity of the ACLF will be assessed by means of a score (CLIF_C ACLF) at the time of admission, day three and seven. Good evolution of the score will be considered when it decreases and bad evolution when it remains the same or increases.
Time frame: one week
Correlate the variation of the score (CLIF-C ACLF) and mortality at 28, 60 and 90 days.
The variation of the score (good or bad evolution) will be correlated with mortality at 28, 60 and 90 days.
Time frame: 90 days
ACLF epidemiological evaluation.
Incidence, prevalence of ACLF will be determined. Triggers (hepatic and / or extra hepatic causes).
Time frame: 90 days
Correlate the level of NGAL with the development of ACLF and its severity evaluated by the CLIF-C ACLF score.
The level of NGAL in plasma and urine will be determined routinely at the time of diagnosis
Time frame: 1 day
No study locations are listed for this record.
Plan to share: No
This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital El Cruce